US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Faron’s Financial Calendar for 2025

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Faron’s Financial Calendar for 2025   Company announcement, 13 December 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the following dates for the Company’s financial reporting in 2025:   February Financial statement release for the full year 2024 and Annual Report27 2024 including financial statements for the full yearAugust Half-year financial

Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Faron Presents Full Analysis of Positive Phase 2 Interim Data from BEXMAB Trial at the 66th American Society of Hematology (ASH) Annual Meeting   Press release, 10 December 2024   Poster highlights -          Overall response rate of 80% (16 out of 20) in refractory or relapsed HMA failed MDS patient population (r/r MDS) -          Observed responses were primarily deep and durable with 70% (14 out of 20) r/r MDS patients achieving complete response (CR) / marrow complete remission (mCR) / partial

Interactions with UK Regulatory Authorities

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Faron Announces Positive Update on Recent Interactions with UK Regulatory Authorities regarding bexmarilimab and expanding the BEXMAB Study to the UK   -          MHRA has awarded bexmarilimab an Innovation Passport for the treatment of relapsed/refractory Myelodysplastic Syndrome and given approval for the BEXMAB trial to be conducted in the UK -          UK sites to join the BEXMAB Study iminently   Press release, 2 December 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North:

Positive Phase 2 Interim Results from BEXMAB Trial

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Inside Information: Faron Announces Positive Phase 2 Interim Results from BEXMAB Trial to be presented at ASH   Company announcement, Inside Information, 27 November 2024   Key highlights -          Interim Phase 2 read-out from the BEXMAB Trial confirms earlier positive Phase 1 & 2 findings in MDS patients with prior HMA failure -          In Phases 1 & 2, 20 MDS patients who are refractory or relapsed on HMA (r/r MDS) and have no effective treatment options, continue to show high objective response

Targeting Soluble Clever-1 for Autoimmune Diseases

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)    Pipeline Update: Targeting Soluble Clever-1 for Autoimmune Diseases   Press release, 11 November 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers and inflammation via novel immunotherapies, today announces the filing of a patent application around the use of soluble Clever-1 for inactivating T-cells and the treatment of autoimmune diseases and inflammatory disorders. The related manuscript can be read

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

(“Faron” or “the Company”)    Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board   Company Announcement, 5 November 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been appointed by a meeting of the Company's five largest shareholders to Faron Pharmaceuticals Oy’s Shareholders' Nomination Board:   · Timo Syrjälä, representing himself (Chair) · Erkka Kohonen,

Faron’s Capital Markets Day 2024

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)    Faron’s Capital Markets Day 2024 – BEXMAB follow-up data and update on drug development pipeline, partnering discussions and introducing new Scientific Advisory Board   Company Announcement, 22 October 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will host a Capital Markets Day for investors, analysts and media today, Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (

Faron announces Capital Markets Day

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Faron announces Capital Markets Day to be held on 22 October 2024   Press release, 7 October 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will host a Capital Markets Day for investors, analysts and media on Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). Speakers include Dr. Mika Kontro, MD, PhD, Associate Professor at

Grant of options

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Grant of options   Company announcement, August 30, 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 100,000 options over new ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable

Faron 2024 Half-Year Financial Results

Faron Pharmaceuticals Ltd. (“Faron” or “the Company”)   Faron Reports Half-Year Financial Results, 1 January – 30 June 2024     Company Announcement, 27 August 2024   Summary Highlights     · Initial preliminary phase II data read-out from the BEXMAB trial confirmed earlier positive phase I findings in myelodysplastic syndrome (MDS) patients that have failed with hypomethylating agent (HMA), reinforcing bexmarilimab’s potential to improve the therapeutic benefit for patients with aggressive hematological malignancies who do not respond to the current standard

FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS   Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   Key highlights -          Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron’s BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS -          FTD further strengthens the bexmarilimab program by offering clinical development and commercialization

Notice of Half-Year Financial Results

Faron Pharmaceuticals Ltd. (“Faron” or the “Company”)   Faron Pharmaceuticals Notice of Half-Year Financial Results   Company Announcement, 20 August 2024   TURKU, Finland – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, will report its unaudited half-year financial results for the six months ended June 30, 2024, on Tuesday, 27 August 2024.   A live hybrid briefing

Traumakine Research Collaboration and DoD Grant

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Faron Announces Traumakine Research Collaboration and DoD Grant   Press release, 13 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company with its lead immune oncology program bexmarilimab, also pursuing induction of CD73 for organ protection, announces it has joined a research consortium that has received a Department of Defense (DoD) Grant to investigate the use of intravenous interferon

Appointment of Chief Financial Officer

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Appointment of Chief Financial Officer   Company announcement, 8 August 2024 at 2:00 a.m. EDT / 7:00 a.m. BST / 9:00 a.m. EEST   TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces the appointment of Yrjö Wichmann, Faron’s current interim Chief Financial Officer (CFO,

Grant of options

Faron Pharmaceuticals Ltd. (“Faron” or “the Company”)   Grant of options   Company announcement, August 7, 2024 at 10.00 a.m. BST / 12:00 p.m. EEST   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 645,000 options over new ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2019 (including its UK and US sub plans). The Options have been

Faron Appoints Dr. Petri Bono as new CMO

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Faron Appoints Dr. Petri Bono as new CMO   Company announcement, 6 August 2024 at 8:30 a.m. BST / 10:30 a.m. EEST   TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in treatment resistant hematological malignancies and solid tumors, is pleased to announce the appointment of Dr. Petri Bono (M.D., Ph.D.) as the new Chief Medical

Faron Announces Positive FDA Feedback

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Inside Information: Faron Announces Positive FDA Feedback   Company announcement, Inside Information, 11 July 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   Key highlights -          Faron had a formal meeting with the FDA to discuss the registrational clinical development plan for bexmarilimab in the treatment myelodysplastic syndrome (MDS). -          The FDA acknowledged the difficulties of running a randomized study with a comparator in the relapsed / refractory setting (r/r) and instead proposed that

Update on settlement

Faron Pharmaceuticals Ltd (“Faron” or the “Company”) Update on settlement under the UK Open Offer and the REX Retail Offer NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO ACQUIRE ANY SECURITIES. PLEASE SEE THE

Holding(s) in Company

The following amendment has been made to the ‘Holding(s) in Company' announcement released on 24 June 2024 at 12:45 p.m. BST under RNS No 6230T.   In Section 7 of the TR-1: Standard form for notification of major holdings, the data in the rows  ‘Resulting situation on the date on which threshold was crossed or reached’ and ‘Position of previous notification (if applicable)’ have been swapped to accurately reflect the reduction in holdings and the crossing of the percentage threshold.   All other details remain unchanged.   The full amended text is shown below.

Holding(s) in Company

TR-1: Standard form for notification of major holdings   NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible) i 1a. Identity of Faron Pharmaceuticalsthe issuer or the Ltdunderlying issuerof existingsharesto which votingrights areattachedii:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer X2. Reason for thenotification(please mark the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe